Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design
- 15 March 2010
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 427 (1), 19-28
- https://doi.org/10.1042/bj20091530
Abstract
The production of selective protein kinase inhibitors is often frustrated by the similarity of the enzyme active sites. For this reason, it is challenging to design inhibitors that discriminate between the three Aurora kinases, which are important targets in cancer drug discovery. We have used a triple-point mutant of Aurora-A (AurAx3) which mimics the active site of Aurora-B to investigate the structural basis of MLN8054 selectivity. The bias toward Aurora-A inhibition by MLN8054 is fully recapitulated by AurAx3in vitro. X-ray crystal structures of the complex suggest that the basis for the discrimination is electrostatic repulsion due to the T217E substitution, which we have confirmed using a single-point mutant. The activation loop of Aurora-A in the AurAx3–MLN8054 complex exhibits an unusual conformation in which Asp274 and Phe275 side chains point into the interior of the protein. There is to our knowledge no documented precedent for this conformation, which we have termed DFG-up. The sequence requirements of the DFG-up conformation suggest that it might be accessible to only a fraction of kinases. MLN8054 thus circumvents the problem of highly homologous active sites. Binding of MLN8054 to Aurora-A switches the character of a pocket within the active site from polar to a hydrophobic pocket, similar to what is observed in the structure of Aurora-A bound to a compound that induces DFG-out. We propose that targeting this pocket may be a productive route in the design of selective kinase inhibitors and describe the structural basis for the rational design of these compounds.Keywords
This publication has 29 references indexed in Scilit:
- Structure-based design of molecular cancer therapeuticsTrends in Biotechnology, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- Small Molecule Recognition of c-Src via the Imatinib-Binding ConformationCell Chemical Biology, 2008
- c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic PenaltyStructure, 2007
- Targeted anti-mitotic therapies: can we improve on tubulin agents?Nature Reviews Cancer, 2007
- Rational design of inhibitors that bind to inactive kinase conformationsNature Chemical Biology, 2006
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- Inhibition of p38 MAP kinase by utilizing a novel allosteric binding siteNature Structural & Molecular Biology, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000